We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Dupixent (dupilumab) is tipped to be the market ... Sanofi says there has been more than 200 applications to receive the drug under the system, which ceases once a drug gains marketing approval.

The final appraisal document for Dupixent (dupilumab ... ILD is a diverse collection of more than 200 lung disorders, and around 13% to 40% of patients go on to develop progressive disease.

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

The business has a 50 day moving average of $49.72 and a 200 day moving average of $52. ... The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology ...

with peanut allergy in the U.S. and Canada to determine the impact of subcutaneous dupilumab (Dupixent; Sanofi, Regeneron) given every 2 weeks on desensitization to peanut exposure by the 24-week ...

It is likely easier for a patient to switch from Humira to Rinvoq, say, than Humira to Dupixent. As impressive ... from its all-time high value of over $200 to $165 per share, practically ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

It has been a commercial failure, blown away by the success of Dupixent, an injectable IL-4 ... which implies there is up to ~200% more upside in play. Arcutis also has two other pipeline products ...

The company has over 200 breweries around the globe and operations ... In September 2024, the US Food and Drug Administration (FDA) approved Dupixent as an add-on maintenance treatment for adults ...